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The advent of biobanks in the field of science and 
technology has seen scientists entering a new age in 
biotechnology research. General ethical considerations, 
which apply to health research involving human 
participants, will apply equally to biobank research. However, in 
addition, there are unique ethical issues specific to biobank research. 
This is because of the nature of biobank research which has evolved to 
include an intersection of disciplines and networks. While the unique 
considerations pertaining to genetic research also apply in this context, 
with biobanks, international collaborations have emerged on a scale 
not previously seen. Without doubt this type of collaborative research 
is pivotal to advancing science, health and well-being. Nevertheless, 
multifaceted ethico-regulatory and social complexities have surfaced, 
including concerns around individual and group autonomy, informed 
consent, privacy, confidentiality, secondary use of samples and data 
over long periods, data sharing, benefit sharing and differing legal 
requirements across national boundaries.[1] Because biobanks are 
essential for major advances in health research, a balance is required 
between the tensions arising from the need for progress towards human 
health and well-being and ethico-regulatory and social concerns.   
In this paper we briefly describe biobanks and the advancement 
from biobanks to networking and sample and data-sharing. We 
discuss how the supremacy of informed consent is challenged by 
this new age research and some of the risks that could occur in 
the context of biobank research. We highlight the importance of 
safeguards like specimen and data access agreements and the pivotal 
role of public trust for the success of this type of research enterprise. 
The need for ethics in the governance of biobanks is underscored. 
Pertinent international and local ethics and governance documents 
are referred to. The legal void in South Africa (SA) with regard to 
biobank research is also discussed. While the ethico-regulatory issues 
relating to biobank research in this paper are not exhaustive, we raise 
what we consider to be the relevant ones.         
Biobanks – a brief description
Biobanks are repositories that store animal, plant and human specimens. 
This paper focuses on biobanks that store human bio logical materials 
(HBMs) specifically for research purposes. Biological materials, as defined 
in the Regulations to the South African National Health Act (NHA)[2] 
are: ‘material from a human being including DNA, RNA, blastomeres, 
polar bodies, cultured cells, embryos, gametes, progenitor stem cells, 
small tissue biopsies and growth factors from the same’.[3] Biobanks 
are repositories that store not only organised collections of HBMs 
usually from a large number of donors but also their associated data, 
including individual health records and information derived from their 
analysis.[1,4] A well-functioning up-to-date biobank serves to accelerate 
important advances in health research as it exploits ‘state-of-the-art 
genetics together with big data sets and individual health records to 
allow for complex and powerful studies’[4] on an unprecedented scale. 
Biobanks collate large numbers of variables and are crucial resources to 
the understanding of genetic, environmental and lifestyle factors in the 
aetiology of disease.[4,5] However, in SA, biobanks are typically concerned 
with the storage of specimens and the crucial bioinformatics capacity of 
these repositories seem to be very much in their nascent stages.[6] 
The two broad categories of biobanks are: 
• those that are  involved in large cohort studies where a minimum 
of tens of thousands of participants is required 
• those that are disease specific.[4] 
Biobanks are repositories that store human biological materials and their associated data. They are rapidly becoming part of national and 
international networks and give rise to unique ethico-regulatory issues. Whether consent is informed and whether this term should be used 
when specimens are collected for biobank research is questionable. Where risks occur, they are usually social and relate to identifiability. 
Public trust and confidence are important for the success of this type of research. Consensus is growing that governance of biobanks 
should be harmonised. Controlled specimen and data access agreements are essential. The South African National Health Act (NHA) and its 
Regulations, that provide the foundation for the legal framework with regard to human tissue and research in South Africa, are silent on the 
issue of biobanks and the law lags behind while science and technology advance rapidly. The use of biobank assets will lead to significant 
benefits in human health and should be encouraged while taking account of the associated ethical, legal and social issues and working 
towards a balance between these two positions. 
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The former are usually referred to as population biobanks and they 
focus on the promotion of population health.[1,7] There is a paucity of 
data on the number and types of biobanks operating in the country. 
A review documented just over a dozen biobanks in the country 
and these operate on a smaller scale.[6] Not all of them are specific 
to research. Those that are involved in human health research are 
usually smaller collections from research projects within academic 
institutions.[6] While the National Health Laboratory Services in SA 
has attempted to establish a population level biobank,[8] this has 
unfortunately not materialised. The reasons for this are probably 
multifactorial but in our opinion include bureaucratic hurdles and 
the lack of a comprehensive ethico-legal framework for biobanks 
in the country. Although the SA regulatory framework makes 
provision for tissue banks, these are not biobanks. Tissue banks are 
defined as ‘an organisation, institution or person that provides or 
engages in one or more services involving cells and/or tissue from 
living or deceased individuals for transplantation purposes’.[9] This 
definition may clearly include a person who provides or engages 
in these activities. Moreover, the uses of cells and/or tissues are 
limited to transplantation purposes only. This inelegant definition 
differs from the internationally recognised definition of a biobank as 
described above. Notably, the NHA,[2] which provides the foundation 
and scaffold for the legal framework regarding human tissue and 
research in SA, is silent on the issue of biobanks. Despite chapter 8 
of the NHA being specific to human tissue and chapter 9 to research, 
none of their regulations provide regulatory direction with regard 
to biobanks.  
Biobanks, networking and data-sharing
Biobanks are conventionally defined in terms of their institutional 
or geographical location. With the emergence of new scientific and 
computer technology development, HBMs and associated data are 
rapidly and increasingly becoming part of a national and international 
network of biobanks. Such networking means that biobanks have 
the greatest potential as resources for translational research.[10] Data 
are shared between biobanks when sample sizes are insufficient to 
produce statistically significant results. Research potential is therefore 
fully realised.[4] The bigger and more networked the biobank, the 
greater the power of the research that can be conducted.[10] Certain 
types of research can only be conducted if there is networking 
between biobanks, e.g. where rare diseases are studied, a single 
researcher may not be able to collect an adequate number of samples. 
Moreover, some common diseases, like cardiac disease, are now seen 
to comprise rare disease subsets characterised by specific genetic 
polymorphisms. Networking also assists in situations where there are 
social and logistical difficulties with obtaining HBMs.[10]
Several categories of biobank networks have evolved over time. These 
categories are neither exhaustive nor non-mutually exclusive and 
include:[10] 
• ‘Storage’ networks – facilities for storage are shared among 
biobanks to reduce costs and improve quality.
• ‘Bring-and-share’ storage networks – lower fee structures are 
offered to researchers to encourage sharing of resources with other 
researchers.
• ‘Catalogue’ networks – maintains a database that can be accessed 
by external researchers looking for samples for their research.
• ‘Partnership’ networks – costs and efforts in recruitment are shared.
• ‘Contribution’ networks – relevant specimens are contributed to 
disease-specific biobanks.
• ‘Expertise’ networks – expertise instead of samples are shared.
South Africa, with its world-class scientists and infrastructure 
conducive to advancing high-quality, high-tech research, is ideally 
placed on the continent to integrate these different categories of 
biobanks and establish networks within the country that would 
maximise the research potential here. Specimens within these 
biobanks are from the public and sharing would not only facilitate 
attaining the desired statistical power and addressing some of the 
financial and other resource constraint issues, but would be a step in 
the direction of the common good. Research, conducted with public 
involvement, is in reality a contract between science and society. 
While ethical challenges specific to those of networking and data-
sharing between biobanks have arisen, these are not insurmountable 
and should not impede much needed human health research. One 
of the greatest concerns is that large-scale networking would result 
in a total disconnect between participants and researchers and as a 
consequence, researchers would become less accountable to donor 
interests.[10] Where biobanks have been approved and are subject to 
oversight by well-functioning, competent research ethics committees 
(REC), donor interests ought to be taken care of adequately.        
Informed consent
A key problem, resulting in a bottleneck between conventional 
established research and biobank research, is the issue of informed 
consent.[1] Informed consent is both an ethical and legal doctrine 
forming a necessary component of health research. Ethical 
challenges in the context of biobank research often focus on the 
tensions between individual autonomy or respect for persons and 
utilitarian justice and the common good.[10] We believe that because 
biobank research involves the contributions of a large number of 
people, its ethical emphasis should hinge on the utilitarian common 
good. Due to the nature of biobank research, the focus on individual 
autonomy and informed consent is seriously challenged. The consent 
emphasis in classic research ethics is that of individual, first-person 
consent for sample collection and use for the specific research 
project that the participant consents to. In addition, the participant 
consents to storage over a defined period of time. We recommend 
and encourage researchers to consider storage in biobanks over an 
indefinite period as such research involves genetic and genomic 
studies where the intergenerational period is at least 25 years. The 
consent and sample collection process with biobank research is often 
separate from the actual research which could be conducted several 
years later, by a group of different researchers, in different biobanks 
as compared to when the initial sample collection took place and 
informed consent was obtained. In addition, the research may 
involve research questions and methods that could not have been 
contemplated at the time of sample collection. Specific cell lines 
could be derived from the samples and these could be duplicated 
and exchanged through the networks.[1] It is therefore questionable 
as to whether consent for biobank research is at all informed and 
whether this term should be used when specimens are collected 
for biobank research. In addition, classic and biobank consent 
forms respect participant autonomy to the extent of including a 
withdrawal clause for the specimens that have been collected. 
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Clearly, with such extensive networking, sharing of specimens, and 
transformation of specimens into cell lines, withdrawing of samples 
will not be as easy as it seems on the consent form and this could be 
perceived as paying ‘lip-service’ to autonomy. Because of this lack 
of knowledge of what will happen to the specimens in the future, 
consent processes must be broad and ‘broad’ consent, ethically and 
legally is not the same as ‘informed’ consent. 
Various models of consent have been offered by ethicists and 
researchers to address the informed consent difficulties encountered 
in biobank research. These include re-consent, tiered consent 
and multi-layered consent with secondary use statements.[1,4,11] 
However, these could result in consent exhaustion on the part of 
the participant and increase the financial costs and administrative 
burdens of the research. Therefore, we advocate obtaining broad 
consent from participants and assuring them that there would be 
REC oversight and approval for future research using their samples 
and data as the most appropriate way forward. This would be in 
line with the SA Department of Health’s research ethics guidelines 
which allows for broad consent and defines it as where the ‘donor 
permits use of biological materials for future studies, subject only 
to further prior ethics review and approval’.[12]  Depending on the 
category of the biobank, differing degrees of broad consent could 
be obtained and range from consent to conducting research in a 
specific sphere in health, or on a specific disease, to unrestricted 
consent for future health research use as in population biobank 
studies.[11] International organisations, for example, the Organisation 
for Economic Cooperation and Development (OECD) advocate this 
type of broad consent for biobank research.[13]                 
The Draft World Medical Association (WMA) Declaration on Ethical 
Considerations Regarding Health Databases and Biobanks[14] which 
has been out for open consultation since March this year, states 
that individuals must be given the choice to decide whether or not 
their biological materials will be included in a biobank. The consent 
process needs to include information on the purpose of the biobank, 
the nature of the material to be collected, who will have access to the 
biobank, the biobank’s governance arrangements and how privacy 
will be protected. It goes on to state that conditional broad consent 
is acceptable if inter alia all information about future use is provided 
during the consent process and all use is approved by a dedicated, 
independent ethics committee. It does not define ‘conditional broad 
consent’. It also does not take into consideration that because of the 
evolving nature of biobank research it is not possible to provide all 
information on future use. It would be interesting to see how the 
WMA defines broad consent. The Draft Declaration states that blanket 
or open consent for future use ‘not envisaged at the time of collection 
is not ethically acceptable’. This, in our opinion, would serve to cripple 
biobank research as many studies emanating from biobanks involve 
research questions and methods not envisaged at the time of sample 
collection. 
Risks of biobank research
It is important to bear in mind that just as there are societal benefits of 
biobank research based on the common good, there are societal risks 
to this type of research. While physical risks of research conducted 
on samples that have already been collected and stored are rare, 
social risks need to be safeguarded against.[1] The nature and degree 
of risk will depend on whether the samples are identifiable and 
the type of information that is linked to the sample. Potential risks 
could extend beyond individual participants to their population 
groups and the general public. Stigmatisation and discrimination, in 
particular genetic discrimination, which are frequently group-based, 
implicating both participants and non-participants, are examples of 
social risks of biobank research. Moreover, when identifiable samples 
are used in research, disclosure of sensitive information could result in 
an invasion of the participant’s privacy.[1] 
Confidentiality is the main ethical concern regarding identifiability. 
It is essential that donors understand the notion of identifiability and 
the different levels of anonymisation in order to assess the individual 
consequences of participation.[15] In addition, biobank research implies 
risk for identifiable groups and communities because anonymity of 
the individual does not necessarily translate to group anonymity. 
Different terms pertaining to identifiability are used for stored tissue 
in different guidelines and literature. Moreover, the same terms have 
different meanings in different guidelines and also, at times, within 
the same guidelines.[15] The latter problem also applies to the SA 
ethics guidelines. Needless to say, confusion and communication 
barriers result. A clear indication of levels of identifiability are offered 
by the following five levels of anonymisation utilised in the European 
Guidelines:[16]
Anonymous
This is appropriate only for archaeological samples. As it is always 
possible to identify the donor through DNA fingerprinting, where 
samples contain any trace of DNA, they are not truly anonymous.[16]
Anonymised 
This term denotes storage of biological material alongside associated 
information like age, medical treatment, etc. However, all identifying 
material is removed either irreversibly (unlinked anonymised) or 
reversibly (linked anonymised). Identification of linked anonymised 
samples is usually by use of a code which researchers and other users 
of the samples do not have access to.[16] 
Coded
Here samples are reversibly linked, anonymised with researchers and 
users having access to the code.[16]
Identified 
These are samples with information allowing identification, e.g. name, 
address, telephone number, etc. Pathology laboratories usually store 
samples in the identified form.[16]
Population databanks, which are mainly longitudinal in nature, 
would require linked anonymised and coded samples. Fears regarding 
problems with recruitment because of the potential for identification 
of the participant must be balanced with utility and the tangible 
benefits of such a process. Research with potential participants has 
shown that such fears could be unfounded.[17]
Controlled sample and data access 
agreements
Participants and the public must have assurance that the scientific 
community will use samples and data from these banks correctly. 
Therefore, to ensure controlled access, sample and data access 
agreements are advocated towards the provision of liberal, but secure 
RESEARCH
58     August 2015, Vol. 8, No. 2, Supplement 1    SAJBL
access of samples and data. While the international guideline on 
prevention of scientific misconduct (Singapore Statement),[18] and the 
Draft WMA’s Declaration on Ethical Considerations Regarding Health 
Databases and Biobanks[14] could have an impact on international 
laws and practices, they are unclear on how to implement processes 
to monitor and regulate research integrity.[19] Problems concerning 
these international documents include:[19]
• Implementing national laws in an internationally consistent 
manner is problematic.
• Immediate, practical solutions for problems that could arise within 
global genomics projects are often not offered.
• An optimal level of protection is not offered as they are not 
contractual in nature and their interpretation and enforcement 
could end up being very costly, unpredictable, lengthy and 
protracted.
It follows therefore, that establishers of biobanks should have strict 
controlled-access policies in place which should be approved by 
a REC. Contractual sample and data access agreements which 
ensure the proper recognition of all in the research production 
chain and adequate protections of research participants have been 
recommended.[19] The HBM recipient has a responsibility similar 
to that of a trustee or steward in order to ensure protection of the 
donated tissues. Material Transfer Agreements (MTAs) are an example 
of such a contractual arrangement. The University of Witwatersrand’s 
Biobanks Ethics Committee has developed an MTA template which 
incorporates both ethical principles and legal requirements for use 
by researchers.[20,21] The need for an MTA prior to samples being 
transferred is a requirement by the Health Professions Council of 
South Africa (HPCSA).[22] The SA ethics guidelines only mention that 
inter-institutional sharing agreements are required to be confirmed 
in writing. There is no further guidance to researchers on how and at 
what stage this should be done. The Draft WMA Declaration is silent 
on the need for contractual specimen and data access agreements.
Public engagement and trust
Consultation with the public and ensuring that they clearly understand 
the functioning of and research conducted by the biobank are some 
of the key factors towards a biobank’s success.[1,4] Ongoing dialogue 
between the public, researchers and biobank managers is essential as 
public support in this context cannot be taken for granted. Moreover, 
public confidence and trust in biobanks research as being done for 
the common good must be cultivated. This is essential to maximise 
participant recruitment and retention of samples. Therefore public 
support is vital to the development of biobanks. 
Two thirds of respondents surveyed in a study that was 
conducted widely throughout Europe had not heard of biobanks 
and most respondents, once aware of the concept, were generally 
supportive.[4] It would be interesting to know what the SA public’s 
response would be to a similar study. A large-scale survey on the 
public’s knowledge, understanding and attitude towards biobanks 
has not been conducted throughout SA as yet. In addition, 
meaningful conversations on biobanks between the public and 
researchers are lacking. If SA wants to be at the forefront of this 
cutting-edge research, commitment is necessary on the part of 
researchers and scientists to build public trust and confidence in 
these activities.    
Biobank governance
Because of extensive networking between biobanks, there is growing 
consensus that governance of biobanks should be harmonised, 
especially if HBMs are to be used broadly.[4,13] In particular, there 
should be harmonisation in the operating procedures and policies 
for procurement, collection, storage and transfer of HBMs if the ob-
jec tive of the biobank, which is that of fostering research, is to be 
realised. Oversight for this should be provided by the REC. In terms of 
the OECD guidelines, the establishment, governance, management, 
operation, access to, use of the biobank and its protocols and processes 
for research activities, oversight mechanisms, strategies for ensuring 
long-term sustainability which also addresses the event that funding is 
terminated or its nature changed, stakeholder consultation (including 
the general public), and criteria for sampling and participant selection, 
should be reviewed and approved by an independent REC.[13] The Draft 
WMA Declaration also requires that an independent REC approves the 
es tablish ment of the biobank.[14] The SA ethics guidelines require that 
all new repositories have prior REC approval and that the REC should es-
tablish procedures to guide this process and the use of the repository.[12] 
A weakness of the SA guidelines, which use the terms repository and 
biobank interchangeably, is that REC oversight with regard to already 
established biobanks is not mandatory. The Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand, the oldest 
REC in the country and among the first to be established in the world 
(1966),[23] set up its Biobanks Ethics Committee in 2013.[20] The mandate 
of this committee is inter alia to review applications for the establishment 
of biobanks and all research pertinent to the use of specimens from the 
approved biobanks.[21,24] This REC oversight of biobanks was commenced 
by the REC despite no local directive to do so. Moreover, the REC is 
guided by the principles of the WMA’s Declaration of Helsinki which 
does not pronounce on biobank oversight.          
Conclusion
The value of biobanks in the health research arena must be 
appreciated by scientists, the public and policymakers alike. The use 
of biobank assets will lead to benefits in diagnosis and the treatment 
of numerous diseases. This should be encouraged while considering 
the associated ethical, legal and social issues and working towards a 
balance between these two requirements. The importance of public 
trust and confidence in this equation must not be underestimated. 
While advances in science and technology are accelerating, the law in 
SA unfortunately lags behind. Fortunately though, some institutions 
have taken their ethics oversight roles seriously and have instituted 
safeguards, despite the legal hiatus in this regard.      
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